{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:38:45Z","timestamp":1790908725510,"version":"4.1.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015068","name":"Universidade de Santiago de Compostela","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015068","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a growing number of biomolecules, including peptides, proteins, monoclonal antibodies and RNA, that could be potentially used for the treatment of central nervous system (CNS) diseases. However, the realization of their potential is being hampered by the extraordinary difficulties these complex biomolecules have to reach the brain in therapeutically meaningful amounts. Nose-to-brain (N-to-B) delivery is now being investigated as a potential option for the direct transport of biomolecules from the nasal cavity to different brain areas. Here, we discuss how different technological approaches enhance this N-to-B transport, with emphasis on those that have shown a potential for clinical translation. We also analyse how the physicochemical properties of nanocarriers and their modification with cell-penetrating peptides (CPPs) and targeting ligands affect their efficacy as N-to-B carriers for biomolecules.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-021-01086-2","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T16:03:06Z","timestamp":1635955386000},"page":"862-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Using nanotechnology to deliver biomolecules from nose to brain \u2014 peptides, proteins, monoclonal antibodies and RNA"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-9444","authenticated-orcid":false,"given":"Mireya L.","family":"Borrajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"1086_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of apical periodontitis: a systematic review and meta-analysis. Alzheimer\u2019s Dement. 2013;9:63\u201375.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1086_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen J, Gustavsson A, Svensson M, Wittchen HU, J\u00f6nsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19:155\u201362.","journal-title":"Eur J Neurol"},{"key":"1086_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMsa1204629","volume":"368","author":"MD Hurd","year":"2013","unstructured":"Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326\u201334.","journal-title":"N Engl J Med"},{"key":"1086_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77:1099\u2013109.","journal-title":"JAMA Neurol"},{"key":"1086_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s11910-012-0297-0","volume":"12","author":"JK Morris","year":"2013","unstructured":"Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer\u2019s disease. Curr Neurol Neurosci Rep. 2013;12:520\u20137.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1086_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.560375","volume":"11","author":"J Berlanga-Acosta","year":"2020","unstructured":"Berlanga-Acosta J, Guill\u00e9n-Nieto G, Rodr\u00edguez-Rodr\u00edguez N, Bringas-Vega ML, Garc\u00eda-del-Barco-Herrera D, Berlanga-Saez JO, et al. Insulin resistance at the crossroad of Alzheimer disease pathology: a review. Front Endocrinol (Lausanne). 2020;11:1\u201322.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1086_CR7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-020-00749-5","volume":"13","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Lemere C, Atri A, Sabbagh M, Salloway S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer\u2019s Res Ther. 2021;13:10\u20132.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1086_CR8","unstructured":"U.S. Food and Drugs Administration. Center for drug evaluation and research. Aducanumab (marked as Aduhelm) Information. Acessed 09.06.21."},{"key":"1086_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","volume":"189","author":"L Kozlovskaya","year":"2014","unstructured":"Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133\u201340.","journal-title":"J Control Release"},{"key":"1086_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2004.08.001","volume":"104","author":"DJ Begley","year":"2004","unstructured":"Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104:29\u201345.","journal-title":"Pharmacol Ther"},{"key":"1086_CR11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of blood-brain barrier. Nat Med. 2013;19:1584\u201396.","journal-title":"Nat Med"},{"key":"1086_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","volume":"35","author":"ZN Warnken","year":"2016","unstructured":"Warnken ZN, Smyth HDC, Watts AB, Weitman S, Kuhn JG, Williams RO. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol. 2016;35:213\u201322.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1086_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"B Engelhardt","year":"2009","unstructured":"Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009;31:497\u2013511.","journal-title":"Semin Immunopathol"},{"key":"1086_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"1086_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, R\u00f6nnb\u00e4ck L, Hansson E. Astrocyte \u2013 endothelial interactions at the blood \u2013 brain barrier. Nat Rev Neurosci. 2006;7:41\u201353.","journal-title":"Nat Rev Neurosci"},{"key":"1086_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s11481-006-9025-3","volume":"1","author":"Y Persidsky","year":"2006","unstructured":"Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1:223\u201336.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1086_CR17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, et al. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des. 2016;22:1177\u201393.","journal-title":"Curr Pharm Des"},{"key":"1086_CR18","doi-asserted-by":"crossref","unstructured":"Furtado D, Bj\u00f6rnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30.","DOI":"10.1002\/adma.201801362"},{"key":"1086_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/aja.1000620106","volume":"62","author":"WM Faber","year":"1937","unstructured":"Faber WM. The nasal mucosa and the subarachnoid space. Am J Anat. 1937;62:121\u201348.","journal-title":"Am J Anat"},{"key":"1086_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1517\/17425247.5.10.1159","volume":"5","author":"H Wu","year":"2008","unstructured":"Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv. 2008;5:1159\u201368.","journal-title":"Expert Opin Drug Deliv"},{"key":"1086_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4155\/tde.14.41","volume":"5","author":"PG Djupesland","year":"2014","unstructured":"Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5:709\u201333.","journal-title":"Ther Deliv"},{"key":"1086_CR22","doi-asserted-by":"crossref","unstructured":"Bruinsmann FA, Vaz GR, De Cristo Soares Alves A, Aguirre T, Pohlmann AR, Guterres SS, et al. Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. 2019;24.","DOI":"10.20944\/preprints201910.0296.v1"},{"key":"1086_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-14845-5","volume":"11","author":"DA Martins","year":"2020","unstructured":"Martins DA, Mazibuko N, Zelaya F, Vasilakopoulou S, Loveridge J, Oates A, et al. Effects of route of administration on oxytocin-induced changes in regional cerebral blood flow in humans. Nat Commun. 2020;11:1\u201316.","journal-title":"Nat Commun"},{"key":"1086_CR24","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/jps.22007","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous sytem: mechanisms and experimental consideration. J Pharm Sci Sci. 2010;99:2386\u201398.","journal-title":"J Pharm Sci Sci"},{"key":"1086_CR25","first-page":"195","volume":"3","author":"MS Landis","year":"2012","unstructured":"Landis MS, Boyden T, Pegg S. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective Ther Deliv. 2012;3:195\u2013208.","journal-title":"An industrial perspective Ther Deliv"},{"key":"1086_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/17425247.2013.790887","volume":"10","author":"CV Pardeshi","year":"2013","unstructured":"Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood\u2013brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10:957\u201372.","journal-title":"Expert Opin Drug Deliv"},{"key":"1086_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10717544.2013.838713","volume":"21","author":"D Mittal","year":"2014","unstructured":"Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21:75\u201386.","journal-title":"Drug Deliv"},{"key":"1086_CR28","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","volume":"26","author":"E Samaridou","year":"2018","unstructured":"Samaridou E, Alonso MJ. Nose-to-brain peptide delivery \u2013 the potential of nanotechnology. Bioorganic Med Chem. 2018;26:2888\u2013905.","journal-title":"Bioorganic Med Chem"},{"key":"1086_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","volume":"128","author":"V Bourganis","year":"2018","unstructured":"Bourganis V, Kammona O, Alexopoulos A, Kiparissides C. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337\u201362.","journal-title":"Eur J Pharm Biopharm"},{"key":"1086_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"L Illum","year":"2000","unstructured":"Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11:1\u201318.","journal-title":"Eur J Pharm Sci"},{"key":"1086_CR31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/10717544.2014.920431","volume":"23","author":"A Kumar","year":"2016","unstructured":"Kumar A, Pandey AN, Jain SK. Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. 2016;23:681\u201393.","journal-title":"Drug Deliv"},{"key":"1086_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","volume":"57","author":"MI Ugwoke","year":"2005","unstructured":"Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57:1640\u201365.","journal-title":"Adv Drug Deliv Rev"},{"key":"1086_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","volume":"61","author":"RA Cone","year":"2009","unstructured":"Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61:75\u201385.","journal-title":"Adv Drug Deliv Rev"},{"key":"1086_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF01153516","volume":"11","author":"DT Moran","year":"1982","unstructured":"Moran DT, Rowley JC, Jaferk BW, Lovell MA. The fine structure of the olfactory mucosa in man. J Neurocytol. 1982;11:721\u201346.","journal-title":"J Neurocytol"},{"key":"1086_CR35","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/156720112803529828","volume":"9","author":"S Gizurarson","year":"2012","unstructured":"Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9:566\u201382.","journal-title":"Curr Drug Deliv"},{"key":"1086_CR36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"A Mistry","year":"2009","unstructured":"Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146\u201357.","journal-title":"Int J Pharm"},{"key":"1086_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","volume":"10","author":"S G\u00e4nger","year":"2018","unstructured":"G\u00e4nger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10:116.","journal-title":"Pharmaceutics"},{"key":"1086_CR38","first-page":"133","volume":"8","author":"FWHM Merkus","year":"2007","unstructured":"Merkus FWHM, Van Den BMP. The blood-brain barrier? Questioning the direct transport theory. 2007;8:133\u201344.","journal-title":"Questioning the direct transport theory"},{"key":"1086_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2377-9-S1-S3","volume":"9","author":"WA Banks","year":"2009","unstructured":"Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9:5\u20139.","journal-title":"BMC Neurol"},{"key":"1086_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2045-8118-8-7","volume":"8","author":"WM Pardridge","year":"2011","unstructured":"Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011;8:2\u20135.","journal-title":"Fluids Barriers CNS"},{"key":"1086_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357022539","volume":"56","author":"L Illum","year":"2004","unstructured":"Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56:3\u201317.","journal-title":"J Pharm Pharmacol"},{"key":"1086_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-9-S3-S5","volume":"9","author":"LR Hanson","year":"2008","unstructured":"Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9:1\u20134.","journal-title":"BMC Neurosci"},{"key":"1086_CR43","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","volume":"12","author":"A Mistry","year":"2015","unstructured":"Mistry A, Stolnik S, Illum L. Nose-to-brain delivery: investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol Pharm. 2015;12:2755\u201366.","journal-title":"Mol Pharm"},{"key":"1086_CR44","first-page":"2088","volume":"46","author":"K Selvaraj","year":"2018","unstructured":"Selvaraj K, Gowthamarajan K, Karri VVSR. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells, Nanomedicine Biotechnol. 2018;46:2088\u201395.","journal-title":"Artif Cells, Nanomedicine Biotechnol"},{"key":"1086_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/mp100029t","volume":"7","author":"NJ Johnson","year":"2010","unstructured":"Johnson NJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm. 2010;7:884\u201393.","journal-title":"Mol Pharm"},{"key":"1086_CR46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","volume":"268","author":"AR Khan","year":"2017","unstructured":"Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release. 2017;268:364\u201389.","journal-title":"J Control Release"},{"key":"1086_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/cne.10143","volume":"444","author":"TE Finger","year":"2002","unstructured":"Finger TE, B\u00f6ttger B, Schaefer ML, Silver WL. Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli. J Comp Neurol. 2002;444:221\u20136.","journal-title":"J Comp Neurol"},{"key":"1086_CR48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1749-6632.2009.03894.x","volume":"1170","author":"WL Silver","year":"2009","unstructured":"Silver WL, Finger TE. The anatomical and electrophysiological basis of peripheral nasal trigeminal chemoreception. Ann N Y Acad Sci. 2009;1170:202\u20135.","journal-title":"Ann N Y Acad Sci"},{"key":"1086_CR49","doi-asserted-by":"crossref","unstructured":"Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2021.","DOI":"10.1007\/s13346-020-00891-5"},{"key":"1086_CR50","doi-asserted-by":"crossref","unstructured":"Yamamoto A, Iseki T, Ochi-Sugiyama M, Okada N, Fujita T, Muranishi S. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcitonin from various mucosal administration sites. J Control Release. 2001;76:363\u201374.","DOI":"10.1016\/S0168-3659(01)00454-0"},{"key":"1086_CR51","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/0306-4522(86)90082-5","volume":"17","author":"JM Hill","year":"1986","unstructured":"Hill JM, Lesniak MA, Pert CB, Roth J. Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience. 1986;17:1127\u201338.","journal-title":"Neuroscience"},{"key":"1086_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0306-4522(89)90036-5","volume":"31","author":"J Unger","year":"1989","unstructured":"Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989;31:143\u201357.","journal-title":"Neuroscience"},{"key":"1086_CR53","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1210\/endo-127-6-3234","volume":"127","author":"JL Marks","year":"1990","unstructured":"Marks JL, Porte D, Stahl WL, Basking DG. Localization of insulin receptor mrna in rat brain by in situ hybridization. Endocrinology. 1990;127:3234\u20136.","journal-title":"Endocrinology"},{"key":"1086_CR54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JAD-1998-1102","volume":"1","author":"XQ Chen","year":"1998","unstructured":"Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey WH. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer\u2019s Dis. 1998;1:35\u201344.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1086_CR55","doi-asserted-by":"crossref","unstructured":"Quintana D, Rokicki J, van der Meer D, Aln\u00e6s D, Kaufmann T, Palomera AC, et al. Oxytocin gene networks in the human brain: a gene expression and large-scale fMRI meta-analysis study. bioRxiv. 2017;149526.","DOI":"10.1101\/149526"},{"key":"1086_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4155\/tde-2018-0002","volume":"9","author":"DS Quintana","year":"2018","unstructured":"Quintana DS, Smerud KT, Andreassen OA, Djupesland PG. Evidence for intranasal oxytocin delivery to the brain: recent advances and future perspectives. Ther Deliv. 2018;9:515\u201325.","journal-title":"Ther Deliv"},{"key":"1086_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/194589240301700208","volume":"17","author":"P Cole","year":"2003","unstructured":"Cole P. The four components of the nasal valve. Am J Rhinol. 2003;17:107\u201310.","journal-title":"Am J Rhinol"},{"key":"1086_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/mp.2015.166","volume":"21","author":"DS Quintana","year":"2016","unstructured":"Quintana DS, Guastella AJ, Westlye LT, Andreassen OA. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry. 2016;21:29\u201338.","journal-title":"Mol Psychiatry"},{"key":"1086_CR59","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41386-018-0241-3","volume":"44","author":"DS Quintana","year":"2019","unstructured":"Quintana DS, Westlye LT, Aln\u00e6s D, Kaufmann T, Mahmoud RA, Smerud KT, et al. Low-dose intranasal oxytocin delivered with breath powered device modulates pupil diameter and amygdala activity: a randomized controlled pupillometry and fMRI study. Neuropsychopharmacology. 2019;44:306\u201313.","journal-title":"Neuropsychopharmacology"},{"key":"1086_CR60","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ar.a.20122","volume":"281","author":"TD Smith","year":"2004","unstructured":"Smith TD, Bhatnagar KP, Tuladhar P, Burrows AM. Distribution of olfactory epithelium in the primate nasal cavity: are microsmia and macrosmia valid morphological concepts? Anat Rec - Part A Discov Mol Cell Evol Biol. 2004;281:1173\u201381.","journal-title":"Anat Rec - Part A Discov Mol Cell Evol Biol"},{"key":"1086_CR61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/01926230600713475","volume":"34","author":"JR Harkema","year":"2006","unstructured":"Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol. 2006;34:252\u201369.","journal-title":"Toxicol Pathol"},{"key":"1086_CR62","first-page":"477","volume":"118","author":"A Cuschieri","year":"1974","unstructured":"Cuschieri A. Enzyme histochemistry of the olfactory mucosa and vomeronasal organ in the mouse. J Anat. 1974;118:477\u201389.","journal-title":"J Anat"},{"key":"1086_CR63","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0169-409X(89)90018-5","volume":"4","author":"VHL Lee","year":"1989","unstructured":"Lee VHL, Yamamoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev. 1989;4:171\u2013207.","journal-title":"Adv Drug Deliv Rev"},{"key":"1086_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1124\/dmd.113.054429","volume":"42","author":"J Hu","year":"2014","unstructured":"Hu J, Sheng L, Li L, Zhou X, Xie F, D\u2019Agostino J, et al. Essential role of the cytochrome P450 enzyme CYP2A5 in olfactory mucosal toxicity of naphthalene. Drug Metab Dispos. 2014;42:23\u20137.","journal-title":"Drug Metab Dispos"},{"key":"1086_CR65","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4155\/fmc.14.77","volume":"6","author":"U Anand","year":"2014","unstructured":"Anand U, Parikh A, Ugwu MC, Agu RU. Drug transporters in the nasal epithelium: an overview of strategies in targeted drug delivery. Future Med Chem. 2014;6:1381\u20139.","journal-title":"Future Med Chem"},{"key":"1086_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-004-9013-3","volume":"22","author":"CL Graff","year":"2005","unstructured":"Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm Res. 2005;22:86\u201393.","journal-title":"Pharm Res"},{"key":"1086_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbr.2006.04.025","volume":"172","author":"JL Tillerson","year":"2006","unstructured":"Tillerson JL, Caudle WM, Parent JM, Gong C, Schallert T, Miller GW. Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor. Behav Brain Res. 2006;172:97\u2013105.","journal-title":"Behav Brain Res"},{"key":"1086_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/chemse\/27.1.7","volume":"27","author":"P Hussar","year":"2002","unstructured":"Hussar P, Tserentsoodol N, Koyama H, Yokoo-Sugawara M, Matsuzaki T, Takami S, et al. The glucose transporter GLUT1 and the tight junction protein occludin in nasal olfactory mucosa. Chem Senses. 2002;27:7\u201311.","journal-title":"Chem Senses"},{"key":"1086_CR69","doi-asserted-by":"crossref","unstructured":"Hanson LR, Fine JM, Svitak AL, Faltesek KA. Intranasal administration of CNS therapeutics to awake mice. J Vis Exp. 2013;4440.","DOI":"10.3791\/4440"},{"key":"1086_CR70","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/cancers5031020","volume":"5","author":"M Van Woensel","year":"2013","unstructured":"Van Woensel M, Wauthoz N, Rosi\u00e8re R, Amighi K, Mathieu V, Lefranc F, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers (Basel). 2013;5:1020\u201348.","journal-title":"Cancers (Basel)"},{"key":"1086_CR71","unstructured":"ClinicalTrials Database. US National Library of Medicine. National Institutes of Health. Accessed 21.05.21."},{"key":"1086_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69:29\u201338.","journal-title":"Arch Neurol"},{"key":"1086_CR73","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40266-021-00845-7","volume":"38","author":"M Rosenbloom","year":"2021","unstructured":"Rosenbloom M, Barclay TR, Kashyap B, Hage L, O\u2019Keefe LR, Svitak A, et al. A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer\u2019s disease. Drugs Aging. 2021;38:407\u201315.","journal-title":"Drugs Aging"},{"key":"1086_CR74","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.2337\/dc14-2319","volume":"38","author":"S Kullmann","year":"2015","unstructured":"Kullmann S, Heni M, Veit R, Scheffler K, Machann J, Haring HU, et al. Selective insulin resistance in homeostatic and cognitivecontrol brain areas in overweight and obese adults. Diabetes Care. 2015;38:1044\u201350.","journal-title":"Diabetes Care"},{"key":"1086_CR75","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1159\/000504551","volume":"110","author":"M Heni","year":"2020","unstructured":"Heni M, Wagner R, Willmann C, Jaghutriz BA, Vosseler A, K\u00fcbler C, et al. Insulin action in the hypothalamus increases second-phase insulin secretion in humans. Neuroendocrinology. 2020;110:929\u201337.","journal-title":"Neuroendocrinology"},{"key":"1086_CR76","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.psyneuen.2014.10.006","volume":"51","author":"BA Tabak","year":"2015","unstructured":"Tabak BA, Meyer ML, Castle E, Dutcher JM, Irwin MR, Han JH, et al. Vasopressin, but not oxytocin, increases empathic concern among individuals who received higher levels of paternal warmth: a randomized controlled trial. Psychoneuroendocrinology. 2015;51:253\u201361.","journal-title":"Psychoneuroendocrinology"},{"key":"1086_CR77","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.psyneuen.2019.04.019","volume":"107","author":"BA Tabak","year":"2019","unstructured":"Tabak BA, Teed AR, Castle E, Dutcher JM, Meyer ML, Bryan R, et al. Null results of oxytocin and vasopressin administration across a range of social cognitive and behavioral paradigms: evidence from a randomized controlled trial. Psychoneuroendocrinology. 2019;107:124\u201332.","journal-title":"Psychoneuroendocrinology"},{"key":"1086_CR78","first-page":"1","volume":"8","author":"D Price","year":"2017","unstructured":"Price D, Burris D, Cloutier A, Thompson CB, Rilling JK, Thompson RR. Dose-dependent and lasting influences of intranasal vasopressin on face processing in men. Front Endocrinol (Lausanne). 2017;8:1\u201315.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1086_CR79","unstructured":"Scopus Database. Elservier. Accessed 06.04.21."},{"key":"1086_CR80","unstructured":"PubMed Database. US National Library of Medicine. National Institutes of Health. Accessed 06.04.21."},{"key":"1086_CR81","first-page":"439","volume":"10","author":"J Trevino","year":"2020","unstructured":"Trevino J, Quispe R, Khan F, Novak V. Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials. 2020;10:439.","journal-title":"J Clin Trials"},{"key":"1086_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1124\/jpet.119.258152","volume":"370","author":"Z Wang","year":"2019","unstructured":"Wang Z, Xiong G, Tsang WC, Sch\u00e4tzlein AG, Uchegbu IF. Nose-to-brain delivery. J Pharmacol Exp Ther. 2019;370:593\u2013601.","journal-title":"J Pharmacol Exp Ther"},{"key":"1086_CR83","doi-asserted-by":"publisher","unstructured":"Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release [Internet]. Elsevier; 2018;281:139\u201377. Available from: https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.011","DOI":"10.1016\/j.jconrel.2018.05.011"},{"key":"1086_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics11020084","volume":"11","author":"MC Bonferoni","year":"2019","unstructured":"Bonferoni MC, Rossi S, Sandri G, Ferrari F, Gavini E, Rassu G, et al. Nanoemulsions for \u201cnose-to-brain\u201d drug delivery. Pharmaceutics. 2019;11:1\u201317.","journal-title":"Pharmaceutics"},{"key":"1086_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jconrel.2019.06.021","volume":"307","author":"YS Kim","year":"2019","unstructured":"Kim YS, Sung DK, Kim H, Kong WH, Kim YE, Hahn SK. Nose-to-brain delivery of hyaluronate \u2013 FG loop peptide conjugate for non-invasive hypoxic-ischemic encephalopathy therapy. J Control Release. 2019;307:76\u201389.","journal-title":"J Control Release"},{"key":"1086_CR86","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijpharm.2010.08.020","volume":"400","author":"D Vllasaliu","year":"2010","unstructured":"Vllasaliu D, Exposito-Harris R, Heras A, Casettari L, Garnett M, Illum L, et al. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm. 2010;400:183\u201393.","journal-title":"Int J Pharm"},{"key":"1086_CR87","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","volume":"190","author":"L Casettari","year":"2014","unstructured":"Casettari L, Illum L. Chitosan in nasal delivery systems for therapeutic drugs. J Control Release. 2014;190:189\u2013200.","journal-title":"J Control Release"},{"key":"1086_CR88","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11095-011-0572-9","volume":"29","author":"SRK Vaka","year":"2012","unstructured":"Vaka SRK, Murthy SN, Balaji A, Repka MA. Delivery of brain-derived neurotrophic factor via nose-to-brain pathway. Pharm Res. 2012;29:441\u20137.","journal-title":"Pharm Res"},{"key":"1086_CR89","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","volume":"108","author":"H Derakhshankhah","year":"2018","unstructured":"Derakhshankhah H, Jafari S. Cell penetrating peptides: a concise review with emphasis on biomedical applications. Biomed Pharmacother. 2018;108:1090\u20136.","journal-title":"Biomed Pharmacother"},{"key":"1086_CR90","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/ph3040961","volume":"3","author":"S Trabulo","year":"2010","unstructured":"Trabulo S, Cardoso AL, Mano M, De Lima MCP. Cell-penetrating peptides\u2014mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals. 2010;3:961\u201393.","journal-title":"Pharmaceuticals"},{"key":"1086_CR91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15171\/bi.2015.10","volume":"5","author":"S Jafari","year":"2017","unstructured":"Jafari S, Maleki Dizaj S, Adibkia K. Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery. BioImpacts. 2017;5:103\u201311.","journal-title":"BioImpacts"},{"key":"1086_CR92","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38:406\u201324.","journal-title":"Trends Pharmacol Sci"},{"key":"1086_CR93","doi-asserted-by":"publisher","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","volume":"269","author":"D Derossi","year":"1994","unstructured":"Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 1994;269:10444\u201350.","journal-title":"J Biol Chem"},{"key":"1086_CR94","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0014-5793(00)02072-X","volume":"482","author":"PEG Thor\u00e9n","year":"2000","unstructured":"Thor\u00e9n PEG, Persson D, Karlsson M, Nord\u00e9n B. The Antennapedia peptide penetratin translocates across lipid bilayers - the first direct observation. FEBS Lett. 2000;482:265\u20138.","journal-title":"FEBS Lett"},{"key":"1086_CR95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-1-4939-2806-4_2","volume":"1324","author":"E Dupont","year":"2015","unstructured":"Dupont E, Prochiantz A, Joliot A. Penetratin story: an overview. Methods Mol Biol. 2015;1324:29\u201337.","journal-title":"Methods Mol Biol"},{"key":"1086_CR96","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1021\/acs.molpharmaceut.5b00854","volume":"13","author":"N Kamei","year":"2016","unstructured":"Kamei N, Shingaki T, Kanayama Y, Tanaka M, Zochi R, Hasegawa K, et al. Visualization and quantitative assessment of the brain distribution of insulin through nose-to-brain delivery based on the cell-penetrating peptide noncovalent strategy. Mol Pharm. 2016;13:1004\u201311.","journal-title":"Mol Pharm"},{"key":"1086_CR97","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acs.molpharmaceut.6b01134","volume":"14","author":"N Kamei","year":"2017","unstructured":"Kamei N, Tanaka M, Choi H, Okada N, Ikeda T, Itokazu R, et al. Effect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouse. Mol Pharm. 2017;14:916\u201327.","journal-title":"Mol Pharm"},{"key":"1086_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-36210-9","volume":"8","author":"N Kamei","year":"2018","unstructured":"Kamei N, Okada N, Ikeda T, Choi H, Fujiwara Y, Okumura H, et al. Effective nose-to-brain delivery of exendin-4 via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction. Sci Rep. 2018;8:1\u201314.","journal-title":"Sci Rep"},{"key":"1086_CR99","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.apsb.2016.04.001","volume":"6","author":"T Lin","year":"2016","unstructured":"Lin T, Liu E, He H, Shin MC, Moon C, Yang VC, et al. Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm Sin B. 2016;6:352\u20138.","journal-title":"Acta Pharm Sin B"},{"key":"1086_CR100","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s10989-019-09971-8","volume":"26","author":"T Miwa","year":"2020","unstructured":"Miwa T, Tachii K, Wei FY, Kaitsuka T, Tomizawa K. Intranasal drug delivery into mouse nasal mucosa and brain utilizing arginine-rich cell-penetrating peptide-mediated protein transduction. Int J Pept Res Ther. 2020;26:1643\u201350.","journal-title":"Int J Pept Res Ther"},{"key":"1086_CR101","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jconrel.2017.03.029","volume":"263","author":"D Yuan","year":"2017","unstructured":"Yuan D, Yi X, Zhao Y, Poon CD, Bullock KM, Hansen KM, et al. Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity. J Control Release. 2017;263:172\u201384.","journal-title":"J Control Release"},{"key":"1086_CR102","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijpharm.2009.05.057","volume":"378","author":"H Yu","year":"2009","unstructured":"Yu H, Kim K. Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits. Int J Pharm. 2009;378:73\u20139.","journal-title":"Int J Pharm"},{"key":"1086_CR103","doi-asserted-by":"publisher","first-page":"11153","DOI":"10.1039\/c3nr02905k","volume":"5","author":"D Ye","year":"2013","unstructured":"Ye D, Raghnaill MN, Bramini M, Mahon E, \u00c5berg C, Salvati A, et al. Nanoparticle accumulation and transcytosis in brain endothelial cell layers. Nanoscale. 2013;5:11153\u201365.","journal-title":"Nanoscale"},{"key":"1086_CR104","doi-asserted-by":"crossref","unstructured":"Fullstone G, Nyberg S, Tian X, Battaglia G. From the blood to the central nervous system: a nanoparticle\u2019s journey through the blood\u2013brain barrier by transcytosis. Int Rev Neurobiol. 2016.","DOI":"10.1016\/bs.irn.2016.06.001"},{"key":"1086_CR105","first-page":"1","volume":"13","author":"VM Pulgar","year":"2019","unstructured":"Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci. 2019;13:1\u20139.","journal-title":"Front Neurosci"},{"key":"1086_CR106","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/jemt.1070230105","volume":"23","author":"EE Morrison","year":"1992","unstructured":"Morrison EE, Costanzo RM. Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Tech. 1992;23:49\u201361.","journal-title":"Microsc Res Tech"},{"key":"1086_CR107","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijbiomac.2013.06.041","volume":"61","author":"M Kumar","year":"2013","unstructured":"Kumar M, Pandey RS, Patra KC, Jain SK, Soni ML, Dangi JS, et al. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int J Biol Macromol. 2013;61:189\u201395.","journal-title":"Int J Biol Macromol"},{"key":"1086_CR108","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1021\/mp5008376","volume":"12","author":"S Yadav","year":"2015","unstructured":"Yadav S, Gattacceca F, Panicucci R, Amiji MM. Comparative biodistribution and pharmacokinetic analysis of cyclosporine-A in the brain upon intranasal or intravenous administration in an oil-in-water nanoemulsion formulation. Mol Pharm. 2015;12:1523\u201333.","journal-title":"Mol Pharm"},{"key":"1086_CR109","doi-asserted-by":"crossref","unstructured":"Manickavasagam D, Lin L, Oyewumi MO. Nose-to-brain co-delivery of repurposed simvastatin and BDNF synergistically attenuates LPS-induced neuroinflammation. Nanomedicine Nanotechnology, Biol Med. 2020;23:102107.","DOI":"10.1016\/j.nano.2019.102107"},{"key":"1086_CR110","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nurt.2009.02.001","volume":"6","author":"MJ Kubek","year":"2009","unstructured":"Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics. 2009;6:359\u201371.","journal-title":"Neurotherapeutics"},{"key":"1086_CR111","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6NR07581A","volume":"9","author":"E Ahmad","year":"2017","unstructured":"Ahmad E, Feng Y, Qi J, Fan W, Ma Y, He H, et al. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale. 2017;9:1174\u201383.","journal-title":"Nanoscale"},{"key":"1086_CR112","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/10611860903055470","volume":"17","author":"A Mistry","year":"2009","unstructured":"Mistry A, Glud SZ, Kjems J, Randel J, Howard KA, Stolnik S, et al. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J Drug Target. 2009;17:543\u201352.","journal-title":"J Drug Target"},{"key":"1086_CR113","doi-asserted-by":"crossref","unstructured":"Sava V, Fihurka O, Khvorova A, Sanchez-Ramos J. Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington\u2019s disease gene expression following intranasal administration. Nanomedicine Nanotechnology, Biol Med. 2020;24:102119.","DOI":"10.1016\/j.nano.2019.102119"},{"key":"1086_CR114","first-page":"1","volume":"11","author":"YZ Zhao","year":"2016","unstructured":"Zhao YZ, Jin RR, Yang W, Xiang Q, Yu WZ, Lin Q, et al. Using gelatin nanoparticle mediated intranasal delivery of neuropeptide substance P to enhance neuro-recovery in hemiparkinsonian rats. PLoS ONE. 2016;11:1\u201318.","journal-title":"PLoS ONE"},{"key":"1086_CR115","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.nano.2013.10.009","volume":"10","author":"YZ Zhao","year":"2014","unstructured":"Zhao YZ, Li X, Lu CT, Lin M, Chen LJ, Xiang Q, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine Nanotechnology, Biol Med. 2014;10:755\u201364.","journal-title":"Nanomedicine Nanotechnology, Biol Med"},{"key":"1086_CR116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.colsurfb.2017.03.035","volume":"154","author":"A Bonaccorso","year":"2017","unstructured":"Bonaccorso A, Musumeci T, Serapide MF, Pellitteri R, Uchegbu IF, Puglisi G. Nose to brain delivery in rats: effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. Colloids Surfaces B Biointerfaces. 2017;154:297\u2013306.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"1086_CR117","first-page":"1373","volume":"7","author":"AP Perez","year":"2012","unstructured":"Perez AP, Mundi\u00f1a-Weilenmann C, Romero EL, Morilla MJ. Increased brain radioactivity by intranasal 32P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine. 2012;7:1373\u201385.","journal-title":"Int J Nanomedicine"},{"key":"1086_CR118","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/03639040802360510","volume":"35","author":"IA Alsarra","year":"2009","unstructured":"Alsarra IA, Hamed AY, Mahrous GM, El Maghraby GM, Al-Robayan AA, Alanazi FK. Mucoadhesive polymeric hydrogels for nasal delivery of acyclovir. Drug Dev Ind Pharm. 2009;35:352\u201362.","journal-title":"Drug Dev Ind Pharm"},{"key":"1086_CR119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2017.11.040","volume":"270","author":"P Picone","year":"2018","unstructured":"Picone P, Sabatino MA, Ditta LA, Amato A, San Biagio PL, Mul\u00e8 F, et al. Nose-to-brain delivery of insulin enhanced by a nanogel carrier. J Control Release. 2018;270:23\u201336.","journal-title":"J Control Release"},{"key":"1086_CR120","first-page":"1189","volume":"55","author":"AD Frankel","year":"1988","unstructured":"Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell Cell Press. 1988;55:1189\u201393.","journal-title":"Cell Cell Press"},{"key":"1086_CR121","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","volume":"272","author":"E Viv\u00e8s","year":"1997","unstructured":"Viv\u00e8s E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997;272:16010\u20137.","journal-title":"J Biol Chem"},{"key":"1086_CR122","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1099\/0022-1317-83-5-1173","volume":"83","author":"J Park","year":"2002","unstructured":"Park J, Ryu J, Kim K-A, Lee HJ, Bahn JH, Han K, et al. Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J Gen Virol. 2002;83:1173\u201381.","journal-title":"J Gen Virol"},{"key":"1086_CR123","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13233-013-1029-2","volume":"21","author":"L Yan","year":"2013","unstructured":"Yan L, Wang H, Jiang Y, Liu J, Wang Z, Yang Y, et al. Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery. Macromol Res. 2013;21:435\u201341.","journal-title":"Macromol Res"},{"key":"1086_CR124","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1016\/j.biomaterials.2013.08.036","volume":"34","author":"T Kanazawa","year":"2013","unstructured":"Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials. 2013;34:9220\u20136.","journal-title":"Biomaterials"},{"key":"1086_CR125","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1021\/mp400644e","volume":"11","author":"T Kanazawa","year":"2014","unstructured":"Kanazawa T, Morisaki K, Suzuki S, Takashima Y. Prolongation of life in rats with malignant glioma by intranasal siRNA\/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol Pharm. 2014;11:1471\u20138.","journal-title":"Mol Pharm"},{"key":"1086_CR126","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/pharmaceutics11090478","volume":"11","author":"T Kanazawa","year":"2019","unstructured":"Kanazawa T, Kurano T, Ibaraki H, Takashima Y, Suzuki T, Seta Y. Therapeutic effects in a transientmiddle cerebral artery occlusion ratmodel by nose-to-brain delivery of anti-TNF-alpha siRNA with cell-penetrating peptide-modified polymer micelles. Pharmaceutics. 2019;11:478.","journal-title":"Pharmaceutics"},{"key":"1086_CR127","doi-asserted-by":"crossref","unstructured":"Ahmad E, Lv Y, Zhu Q, Qi J, Dong X, Zhao W, et al. TAT modification facilitates nose-to-brain transport of intact mPEG-PDLLA micelles: evidence from aggregation-caused quenching probes. Appl Mater Today. 2020;19.","DOI":"10.1016\/j.apmt.2020.100556"},{"key":"1086_CR128","doi-asserted-by":"publisher","first-page":"9888","DOI":"10.1016\/j.biomaterials.2011.09.004","volume":"32","author":"H Xia","year":"2011","unstructured":"Xia H, Gao X, Gu G, Liu Z, Zeng N, Hu Q, et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials. 2011;32:9888\u201398.","journal-title":"Biomaterials"},{"key":"1086_CR129","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijpharm.2017.07.077","volume":"530","author":"T Kanazawa","year":"2017","unstructured":"Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, et al. Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide. Int J Pharm. 2017;530:195\u2013200.","journal-title":"Int J Pharm"},{"key":"1086_CR130","doi-asserted-by":"crossref","unstructured":"Samaridou E, Walgrave H, Salta E, \u00c1lvarez DM, Castro-L\u00f3pez V, Loza M, et al. Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases. Biomaterials. 2020;230:119657.","DOI":"10.1016\/j.biomaterials.2019.119657"},{"key":"1086_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00697","volume":"11","author":"J Xie","year":"2020","unstructured":"Xie J, Bi Y, Zhang H, Dong S, Teng L, Lee RJ, et al. Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application. Front Pharmacol. 2020;11:1\u201323.","journal-title":"Front Pharmacol"},{"key":"1086_CR132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-020-00755-7","volume":"19","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Guo P, Ma Z, Lu P, Kebebe D, Liu Z. Combination of cell-penetrating peptides with nanomaterials for the potential therapeutics of central nervous system disorders: a review. J Nanobiotechnology. 2021;19:1\u201322.","journal-title":"J Nanobiotechnology"},{"key":"1086_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-01279-1","volume":"7","author":"M Van Woensel","year":"2017","unstructured":"Van Woensel M, Mathivet T, Wauthoz N, Rosi\u00e8re R, Garg AD, Agostinis P, et al. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Sci Rep. 2017;7:1\u201314.","journal-title":"Sci Rep"},{"key":"1086_CR134","doi-asserted-by":"crossref","unstructured":"Sukumar UK, Bose RJC, Malhotra M, Babikir HA, Afjei R, Robinson E, et al. Intranasal delivery of targeted polyfunctional gold\u2013iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials. 2019;218:119342.","DOI":"10.1016\/j.biomaterials.2019.119342"},{"key":"1086_CR135","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jddst.2017.11.013","volume":"43","author":"J Sanchez-Ramos","year":"2018","unstructured":"Sanchez-Ramos J, Song S, Kong X, Foroutan P, Martinez G, Dominguez-Viqueria W, et al. Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain. J Drug Deliv Sci Technol. 2018;43:453\u201360.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1086_CR136","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","volume":"134","author":"O Gartziandia","year":"2015","unstructured":"Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surfaces B Biointerfaces. 2015;134:304\u201313.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"1086_CR137","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1166\/jbn.2016.2313","volume":"12","author":"O Gartziandia","year":"2016","unstructured":"Gartziandia O, Herr\u00e1n E, Ruiz-Ortega JA, Miguelez C, Igartua M, Lafuente JV, et al. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson\u2019s disease. J Biomed Nanotechnol. 2016;12:2220\u201330.","journal-title":"J Biomed Nanotechnol"},{"key":"1086_CR138","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0006-8993(78)90140-3","volume":"152","author":"ME Schwab","year":"1978","unstructured":"Schwab ME, Javoy-Agid F, Agid Y. Labeled wheat germ agglutinin (WGA) as a new, highly sensitive retrograde tracer in the rat brain hippocampal system. Brain Res. 1978;152:145\u201350.","journal-title":"Brain Res"},{"key":"1086_CR139","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1046\/j.1471-4159.1994.62062404.x","volume":"62","author":"WA Banks","year":"1994","unstructured":"Banks WA, Broadwell RD. Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin, and albumin: pharmacokinetic and morphological assessments. J Neurochem. 1994;62:2404\u201319.","journal-title":"J Neurochem"},{"key":"1086_CR140","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/10611869808997885","volume":"6","author":"M Wirth","year":"1998","unstructured":"Wirth M, Hamilton G, Gabor F. Lectin-mediated drug targeting: quantification of binding and internalization of wheat germ agglutinin and Solanum tuberosum lectin using Caco-2 and HT-29 cells. J Drug Target. 1998;6:95\u2013104.","journal-title":"J Drug Target"},{"key":"1086_CR141","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2007.05.026","volume":"121","author":"X Gao","year":"2007","unstructured":"Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release. 2007;121:156\u201367.","journal-title":"J Control Release"},{"key":"1086_CR142","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s11095-011-0641-0","volume":"29","author":"Q Liu","year":"2012","unstructured":"Liu Q, Shen Y, Chen J, Gao X, Feng C, Wang L, et al. Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles. Pharm Res. 2012;29:546\u201358.","journal-title":"Pharm Res"},{"key":"1086_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.01165","volume":"11","author":"Y Su","year":"2020","unstructured":"Su Y, Sun B, Gao X, Dong X, Fu L, Zhang Y, et al. Intranasal delivery of targeted nanoparticles loaded with miR-132 to brain for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11:1\u201313.","journal-title":"Front Pharmacol"},{"key":"1086_CR144","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.nano.2018.10.013","volume":"18","author":"R Li","year":"2019","unstructured":"Li R, Huang Y, Chen L, Zhou H, Zhang M, Chang L, et al. Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke. Nanomedicine Nanotechnology, Biol Med. 2019;18:380\u201390.","journal-title":"Nanomedicine Nanotechnology, Biol Med"},{"key":"1086_CR145","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF01002469","volume":"21","author":"B Lundh","year":"1989","unstructured":"Lundh B, Brockstedt U, Kristensson K. Lectin-binding pattern of neuroepithelial and respiratory epithelial cells in the mouse nasal cavity. Histochem J. 1989;21:33\u201343.","journal-title":"Histochem J"},{"key":"1086_CR146","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/1061186X.2011.622396","volume":"20","author":"J Chen","year":"2012","unstructured":"Chen J, Zhang C, Liu Q, Shao X, Feng C, Shen Y, et al. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations. J Drug Target. 2012;20:174\u201384.","journal-title":"J Drug Target"},{"key":"1086_CR147","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","volume":"461","author":"C Zhang","year":"2014","unstructured":"Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease. Int J Pharm. 2014;461:192\u2013202.","journal-title":"Int J Pharm"},{"key":"1086_CR148","doi-asserted-by":"crossref","unstructured":"Li J, Wu H, Hong J, Xu X, Yang H, Wu B, et al. Odorranalectin is a small peptide lectin with potential for drug delivery and targeting. PLoS One. 2008;3:e2381.","DOI":"10.1371\/journal.pone.0002381"},{"key":"1086_CR149","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3109\/10717544.2011.596583","volume":"18","author":"Z Wen","year":"2011","unstructured":"Wen Z, Yan Z, He R, Pang Z, Guo L, Qian Y, et al. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration. Drug Deliv. 2011;18:555\u201361.","journal-title":"Drug Deliv"},{"key":"1086_CR150","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jconrel.2011.02.022","volume":"151","author":"Z Wen","year":"2011","unstructured":"Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson\u2019s disease following intranasal administration. J Control Release. 2011;151:131\u20138.","journal-title":"J Control Release"},{"key":"1086_CR151","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ejpb.2011.10.012","volume":"80","author":"H Wu","year":"2012","unstructured":"Wu H, Li J, Zhang Q, Yan X, Guo L, Gao X, et al. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-\u03b2 25\u201335-treated rats following intranasal administration. Eur J Pharm Biopharm. 2012;80:368\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"1086_CR152","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11373-006-9121-7","volume":"14","author":"R Huang","year":"2007","unstructured":"Huang R, Ke W, Qu Y, Zhu J, Pei Y, Jiang C. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci. 2007;14:121\u20138.","journal-title":"J Biomed Sci"},{"key":"1086_CR153","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.biomaterials.2007.09.024","volume":"29","author":"R Huang","year":"2008","unstructured":"Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29:238\u201346.","journal-title":"Biomaterials"},{"key":"1086_CR154","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","volume":"321","author":"M Agrawal","year":"2020","unstructured":"Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Patel RJ, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020;321:372\u2013415.","journal-title":"J Control Release"},{"key":"1086_CR155","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1016\/j.biomaterials.2013.02.003","volume":"34","author":"Z Liu","year":"2013","unstructured":"Liu Z, Jiang M, Kang T, Miao D, Gu G, Song Q, et al. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials. 2013;34:3870\u201381.","journal-title":"Biomaterials"},{"key":"1086_CR156","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1021\/acs.molpharmaceut.7b00158","volume":"14","author":"M Oswald","year":"2017","unstructured":"Oswald M, Geissler S, Goepferich A. Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. Mol Pharm. 2017;14:2177\u201396.","journal-title":"Mol Pharm"},{"key":"1086_CR157","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/10717544.2020.1760960","volume":"27","author":"R Hao","year":"2020","unstructured":"Hao R, Sun B, Yang L, Ma C, Li S. RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery. Drug Deliv. 2020;27:772\u201381.","journal-title":"Drug Deliv"},{"key":"1086_CR158","doi-asserted-by":"crossref","unstructured":"Gallardo-Toledo E, Tapia-Arellano A, Celis F, Sinai T, Campos M, Kogan MJ, et al. Intranasal administration of gold nanoparticles designed to target the central nervous system: fabrication and comparison between nanospheres and nanoprisms. Int J Pharm. 2020;590:119957.","DOI":"10.1016\/j.ijpharm.2020.119957"},{"key":"1086_CR159","doi-asserted-by":"crossref","unstructured":"Pan L, Zhou J, Ju F, Zhu H. Intranasal delivery of \u03b1-asarone to the brain with lactoferrin-modified mPEG-PLA nanoparticles prepared by premix membrane emulsification. Drug Deliv Transl Res.\u00a02018;8:83\u201396.","DOI":"10.1007\/s13346-017-0438-8"},{"key":"1086_CR160","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.2147\/IJN.S120939","volume":"11","author":"CC Bi","year":"2016","unstructured":"Bi CC, Wang AP, Chu YC, Liu S, Mu HJ, Liu WH, et al. Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson\u2019s disease treatment. Int J Nanomedicine. 2016;11:6547\u201359.","journal-title":"Int J Nanomedicine"},{"key":"1086_CR161","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/IJN.S151475","volume":"13","author":"X Yan","year":"2018","unstructured":"Yan X, Xu L, Bi C, Duan D, Chu L, Yu X, et al. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. Int J Nanomedicine. 2018;13:273\u201381.","journal-title":"Int J Nanomedicine"},{"key":"1086_CR162","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","volume":"26","author":"S Tang","year":"2019","unstructured":"Tang S, Wang A, Yan X, Chu L, Yang X, Song Y, et al. Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease. Drug Deliv. 2019;26:700\u20137.","journal-title":"Drug Deliv"},{"key":"1086_CR163","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/IJN.S151474","volume":"13","author":"Q Meng","year":"2018","unstructured":"Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int J Nanomedicine. 2018;13:705\u201318.","journal-title":"Int J Nanomedicine"},{"key":"1086_CR164","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.maturitas.2011.12.015","volume":"73","author":"F Re","year":"2012","unstructured":"Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas. 2012;73:45\u201351.","journal-title":"Maturitas"},{"key":"1086_CR165","first-page":"1","volume":"10","author":"DM Teleanu","year":"2018","unstructured":"Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood-brain delivery methods using nanotechnology Pharmaceutics. 2018;10:1\u201316.","journal-title":"Blood-brain delivery methods using nanotechnology Pharmaceutics"},{"key":"1086_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2020.00305","volume":"14","author":"A Kumar","year":"2020","unstructured":"Kumar A, Chaudhary RK, Singh R, Singh SP, Wang SY, Hoe ZY, et al. Nanotheranostic applications for detection and targeting neurodegenerative diseases. Front Neurosci. 2020;14:1\u201311.","journal-title":"Front Neurosci"},{"key":"1086_CR167","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.2174\/0929867321666140217125857","volume":"21","author":"S Tiwari","year":"2014","unstructured":"Tiwari S, Chaturvedi R. Peptide therapeutics in neurodegenerative disorders. Curr Med Chem. 2014;21:2610\u201331.","journal-title":"Curr Med Chem"},{"key":"1086_CR168","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.biopha.2018.04.025","volume":"103","author":"MH Baig","year":"2018","unstructured":"Baig MH, Ahmad K, Saeed M, Alharbi AM, Barreto GE, Ashraf GM, et al. Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. Biomed Pharmacother. 2018;103:574\u201381.","journal-title":"Biomed Pharmacother"},{"key":"1086_CR169","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coph.2019.02.007","volume":"47","author":"G Guidotti","year":"2019","unstructured":"Guidotti G, Brambilla L, Rossi D. Peptides in clinical development for the treatment of brain tumors. Curr Opin Pharmacol. 2019;47:102\u20139.","journal-title":"Curr Opin Pharmacol"},{"key":"1086_CR170","doi-asserted-by":"crossref","unstructured":"Narayanaswamy R, Wang T, P. Torchilin V. Improving peptide applications using nanotechnology. Curr Top Med Chem. 2015;16:253\u201370.","DOI":"10.2174\/1568026615666150817100338"},{"key":"1086_CR171","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1073\/pnas.0702170104","volume":"104","author":"BJ Spencer","year":"2007","unstructured":"Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A. 2007;104:7594\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1086_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2020;11:1\u201327.","journal-title":"Front Aging Neurosci"},{"key":"1086_CR173","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jconrel.2016.01.017","volume":"224","author":"YZ Zhao","year":"2016","unstructured":"Zhao YZ, Lin M, Lin Q, Yang W, Yu XC, Tian FR, et al. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model. J Control Release. 2016;224:165\u201375.","journal-title":"J Control Release"},{"key":"1086_CR174","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767\u201374.","journal-title":"Nat Rev Drug Discov"},{"key":"1086_CR175","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","volume":"12","author":"NAPS Buss","year":"2012","unstructured":"Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, De Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12:615\u201322.","journal-title":"Curr Opin Pharmacol"},{"key":"1086_CR176","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","volume":"122","author":"Z Elgundi","year":"2017","unstructured":"Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2017;122:2\u201319.","journal-title":"Adv Drug Deliv Rev"},{"key":"1086_CR177","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1080\/10717544.2018.1494226","volume":"25","author":"L Chu","year":"2018","unstructured":"Chu L, Wanga A, Ni L, Yan X, Song Y, Zhao M, et al. Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv. 2018;25:1634\u201341.","journal-title":"Drug Deliv"},{"key":"1086_CR178","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/13543770802680195","volume":"19","author":"SP Mathupala","year":"2009","unstructured":"Mathupala SP. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat. 2009;19:137\u201340.","journal-title":"Expert Opin Ther Pat"},{"key":"1086_CR179","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fnmol.2016.00129","volume":"9","author":"MM Wen","year":"2016","unstructured":"Wen MM. Getting miRNA therapeutics into the target cells for neurodegenerative diseases: a mini-review. Front Mol Neurosci. 2016;9:129.","journal-title":"Front Mol Neurosci"},{"key":"1086_CR180","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41587-019-0204-1","volume":"37","author":"BL Davidson","year":"2019","unstructured":"Davidson BL. Doubling down on siRNAs in the brain. Nat Biotechnol. 2019;37:865\u20136.","journal-title":"Nat Biotechnol"},{"key":"1086_CR181","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","volume":"313","author":"SWL Lee","year":"2019","unstructured":"Lee SWL, Paoletti C, Campisi M, Osaki T, Adriani G, Kamm RD, et al. MicroRNA delivery through nanoparticles. J Control Release. 2019;313:80\u201395.","journal-title":"J Control Release"},{"key":"1086_CR182","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2016.02.032","volume":"227","author":"M Van Woensel","year":"2016","unstructured":"Van Woensel M, Wauthoz N, Rosi\u00e8re R, Mathieu V, Kiss R, Lefranc F, et al. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release. 2016;227:71\u201381.","journal-title":"J Control Release"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01086-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01086-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T14:21:47Z","timestamp":1675866107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01086-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,3]]},"references-count":182,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01086-2","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,3]]},"assertion":[{"value":"20 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have read the final version and give their consents for the article to be published in Drug Delivery and Translational Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}